On September 27, 2024, at 1:50 PM EST, Cumberland Pharmaceuticals (CPIX, Financial) saw its stock price rise rapidly by 5.69%. The stock is currently trading at $1.30 per share with a trading volume of 15,366 shares. The turnover rate stands at 0.11%, with a volatility of 8.10%.
Recent financial reports show that the company achieved a revenue of $9.85 million, a net loss of $1.09 million, an earnings per share of -$0.08, and a gross profit of $7.00 million. The price-to-earnings ratio is -1.81.
Currently, no institutions have provided a "buy," "hold," or "sell" rating for CPIX stock.
The pharmaceutical industry, where CPIX operates, has experienced an overall decline of 1.65%. Notable gainers in the industry include Bioage Labs, Inc., Mira Pharmaceuticals, Inc., and Scilex Holding Company. Active stocks in the sector are Su Xuantang, Mira Pharmaceuticals, Inc., and Sonoma Pharmaceuticals, Inc., with turnover rates of 83.13%, 8.09%, and 6.40% respectively. Stocks with significant volatility include Su Xuantang, Mira Pharmaceuticals, Inc., and Biofrontera Inc C/Wts 27/10/2026 (To Pur Com), with volatility rates of 28.89%, 15.85%, and 15.42% respectively.
Cumberland Pharmaceuticals is a specialty pharmaceutical company focused on acquiring, developing, and commercializing branded prescription products. The company primarily targets hospital acute care, gastroenterology, rheumatology, and oncology markets. They promote approved products through their hospital, field, and oncology sales divisions in the U.S. and establish a global partnership network to register and supply medicines in various countries. Their revenue mainly comes from sales of FDA-approved branded products, including Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol, and Vibativ.
